SWOG 0514: A Phase II Study of Sorafenib in Patients With Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma

Investigational New Drugs - Netherlands
doi 10.1007/s10637-011-9719-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

A Phase II Trial of Gemcitabine and Capecitabine in Patients With Unresectable or Metastatic Gallbladder Cancer or Cholangiocarcinoma: Southwest Oncology Group Study S0202

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2011English

A Prospective Phase II Study of Combined Androgen Blockade in Patients With Androgen Receptor-Positive Metastatic or Locally Advanced Unresectable Salivary Gland Carcinoma

Annals of Oncology
MedicineOncologyHematology
2018English

Sorafenib Continuation or Discontinuation in Patients With Unresectable Hepatocellular Carcinoma After a Complete Response

Oncotarget
Oncology
2015English

Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2009English

Results of a Prospective Phase 2 Study of Pazopanib in Patients With Surgically Unresectable or Metastatic Chondrosarcoma

Cancer
Cancer ResearchOncology
2019English

A Phase II Study of Axalimogene Filolisbac for Patients With Previously Treated, Unresectable, Persistent/Recurrent Loco-Regional or Metastatic Anal Cancer

Oncotarget
Oncology
2020English

A Phase II Study of NK012, a Polymeric Micelle Formulation of SN-38, in Unresectable, Metastatic or Recurrent Colorectal Cancer Patients

Cancer Chemotherapy and Pharmacology
Cancer ResearchToxicologyOncologyPharmacology
2018English

A Clinical Phase II Study of Sorafenib in Advanced Hepatocellular Carcinoma

Anaplastology
2012English

Phase II Study of Cediranib in Patients With Malignant Pleural Mesothelioma: SWOG S0509

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2011English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy